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Removal of lead from gasoline and other envi-
ronmental sources has decreased the median
blood lead concentration ([BPb]) of children in
the United States < 10 µg/dL: the current low
level of concern [Centers for Disease Control
and Prevention (CDC) 1991]. However, there
is compelling cross-sectional and prospective
epidemiological evidence that [BPb] in children
≤ 10 µg/dL causes cognitive decline (Canﬁeld
et al. 2003; Hu et al. 2006; Lanphear et al.
2005; Rothenberg et al. 2002; Winneke et al.
1990). Recently, Gilbert and Weiss (2006) sug-
gested that the BPb action level in children
should be 2 µg/dL. Developmental lead expo-
sure also has been linked to a variety of neuro-
logical and neurodegenerative disorders in
children and adolescents, including attention
deﬁcit hyperactivity disorder (ADHD) (Braun
et al. 2006), auditory and language impair-
ments (Dietrich et al. 1992; Rothenberg et al.
2000; Yuan et al. 2006), retinal deficits
(Rothenberg et al. 2002), neuromotor dysfunc-
tion (Bhattacharya et al. 1990, 2006; Ris et al.
2004), and schizophrenia (Opler et al. 2004).
Few studies, however, have examined the
long-term effects of low-level gestational lead
exposure (GLE) despite ﬁndings that children
with prenatal lead exposure have reduced cog-
nitive functions (Baghurst et al. 1992; Hu et al.
2006; Schnaas et al. 2006; Wasserman et al.
2000), neuromotor and visual motor dysfunc-
tion (Ris et al. 2004; Wasserman et al. 2000),
and altered auditory and retinal function
(Dietrich et al. 1992; Rothenberg et al. 2000,
2002; Wasserman et al. 2000).
Maternal lead exposure results from
inhalation, diet, and/or eating in lead-contam-
inated work areas (Correa et al. 2006; Min
et al. 1996). Maternal skeletal bone lead from
prior exposure mobilizes during pregnancy
and lactation (Manton et al. 2003). Lead eas-
ily crosses the placental and mammary barriers
(Bornschein et al. 1977; Korpela et al. 1986).
Thus, the developing fetus and child are at risk,
as evidenced by ﬁndings that fetal and maternal
[BPb] are similar (Korpela et al. 1986).
The adverse cognitive consequences of
prenatal and postnatal exposure to moderate-
level ([BPb] 11–39 µg/dL) and high-level
([BPb] ≥ 40 µg/dL) lead have been studied in
rodents (Cory-Slechta 1997; Crofton et al.
1980; Kuhlmann et al. 1997; Wasserman
et al. 2000). Several reports also link moder-
ate-to-high-level lead exposure to altered
motor activity (Crofton et al. 1980; Ma et al.
1999) and dopaminergic signaling (Antonio
and Leret 2000; Cory-Slechta 1997). To date,
there are no experimental studies on the
effects and mechanisms of low-level GLE on
neuromotor function, despite evidence that
low-level lead exposure produces these deﬁcits
in children (vide supra).
In this report we present a new model of
human equivalent GLE and the sex-specific
physiological, behavioral, and neurochemical
abnormalities in year-old GLE mice. These
studies were conducted because the long-term
consequences of GLE are unknown and
increasing evidence indicates that early devel-
opmental exposure to neurotoxicants acceler-
ates age-related functional decline and/or
produces delayed neurotoxicity (Barone et al.
1995; Basha et al. 2005; Landrigan et al.
2005; Newland and Rasmussen 2000; Rice
and Barone 2000; Weiss 1990; Weiss et al.
2002). Sex differences were examined because
a) early developmental lead exposure produces
a heightened risk for attention, visual motor,
and ﬁne-motor deﬁcits in males (Bhattacharya
et al. 1990, 2006; Ris et al. 2004); b) male
and female animals exhibit differences in
exposure and susceptibility to chemicals and
lead neurotoxicity (Cory-Slechta et al. 2004;
Vahter et al. 2007); and c) this is an important
and underexplored area of toxicology (Vahter
et al. 2007). Our results show that GLE pro-
duced age-related, sex-specific, and non-
monotonic dose–response alterations.
Materials and Methods
Animals. All experimental and animal care
procedures were in compliance with the
National Institutes of Health (NIH) Public
Health Service Policy on Humane Care and Use
of Laboratory Animals (NIH 2002) and
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BACKGROUND: Low-level developmental lead exposure is linked to cognitive and neurological
disorders in children. However, the long-term effects of gestational lead exposure (GLE) have
received little attention. 
OBJECTIVES: Our goals were to establish a murine model of human equivalent GLE and to deter-
mine dose–response effects on body weight, motor functions, and dopamine neurochemistry in
year-old offspring.
METHODS: We exposed female C57BL/6 mice to water containing 0, 27 (low), 55 (moderate), or
109 ppm (high) of lead from 2 weeks prior to mating, throughout gestation, and until postnatal
day 10 (PN10). Maternal and litter measures, blood lead concentrations ([BPb]), and body weights
were obtained throughout the experiment. Locomotor behavior in the absence and presence of
amphetamine, running wheel activity, rotarod test, and dopamine utilization were examined in
year-old mice.
RESULTS: Peak [BPb] were < 1, ≤10, 24–27, and 33–42 µg/dL in control, low-, moderate- and
high-dose GLE groups at PN0–10, respectively. Year-old male but not female GLE mice exhibited
late-onset obesity. Similarly, we observed male-specific decreased spontaneous motor activity,
increased amphetamine-induced motor activity, and decreased rotarod performance in year-old
GLE mice. Levels of dopamine and its major metabolite were altered in year-old male mice,
although only forebrain utilization increased. GLE-induced alterations were consistently larger in
low-dose GLE mice.
CONCLUSIONS: Our novel results show that GLE produced permanent male-speciﬁc deﬁcits. The
nonmonotonic dose-dependent responses showed that low-level GLE produced the most adverse
effects. These data reinforce the idea that lifetime measures of dose–response toxicant exposure
should be a component of the neurotoxic risk assessment process.
KEY WORDS: aging, amphetamine, balance, dopamine, fetal, sex, gestation, lead, motor activity,
obesity. Environ Health Perspect 116:355–361 (2008). doi:10.1289/ehp.10862 available via
http://dx.doi.org/ [Online 7 December 2007]approved by the Institutional Animal Care and
Use Committee of the University of Houston.
All animals were treated humanely and with
regard for alleviation of suffering. Five-week-
old female and male C57BL/6 mice (Harlan
Sprague Dawley, Inc., Indianapolis, IN) were
housed in a room with a 12:12-hr light:dark
cycle as described previously (He et al. 2003).
Two animal models were used: GLE and post-
natal-only lead exposure (PLE). For each, dams
were mated with a single male overnight, and
the presence of a vaginal plug was recorded as
gestational day 0.5. Dams were weighed twice
weekly until postnatal day (PN) 21 (weaning).
On the day of birth (PN0), the number of
pups and the sex and weight of the offspring
were recorded (12–18 litters per group). On
PN1, litters were culled to six pups with equal
number of males and females when possible.
Pups were weighed on PN7, 10, and 21. At
weaning, male and female mice were indepen-
dently housed four to five per cage and
weighed at 2, 6, 10, and 12 months of age.
Control and lead drinking bottles were
weighed and replaced every other day.
Gestational lead exposure model. Two
weeks after arrival, female mice were singly
housed and randomly divided into four exper-
imental groups: one control and three GLE
groups. Control dams received tap water, and
GLE dams received one of three lead acetate
drinking solutions (Fisher Scientific,
Pittsburgh, PA): 0.005% (27 ppm lead = low-
dose GLE), 0.01% (55 ppm lead = moderate-
dose GLE), or 0.02% (109 ppm lead =
high-dose GLE). Lead drinking solutions were
provided to dams 2 weeks prior to mating to
ensure [BPb] stabilization and a lead body
burden throughout gestation and until PN10.
Control males were used once for breeding
with lead-exposed dams. We selected the pre-
natal through PN10 period for our GLE study
(Figure 1) because rodent brain and retinal
development during this period is equivalent
to that during human gestation (Dobbing and
Sands 1979; Raedler and Sievers 1975; Rice
and Barone 2000). Our overall goal was to
compare the behavioral and neurochemical
changes in low-level and high-level year-old
GLE mice with those in controls. Therefore,
these sets of studies were not conducted in the
moderate-level GLE group.
Postnatal lead exposure model. This model
was established to compare the [BPb] proﬁles
and body weight measures with those in GLE
mice. Four weeks after arrival, female mice
were singly housed and randomly divided into
three experimental groups: one control and
two PLE groups. Upon delivery and through-
out lactation (PN0–21), PLE dams received
either a 0.005% (low-dose PLE) or 0.01%
(moderate-dose PLE) lead drinking solution.
Blood lead concentrations. After decapita-
tion, we measured trunk [BPb] in GLE dams
after 14 days of lead pretreatment and on
PN0. Trunk [BPb] was measured in GLE off-
spring at PN0, 10, 21, 30, 60, and 1 year of
age and in PLE offspring at PN7, 14, 21, 30,
60, and 1 year of age. Values (micrograms per
deciliter) represent the mean ± SE for 10–15
male and female mice per age per group.
Samples were analyzed by anodic stripping
voltammetry using LeadCare Kit I (sensitiv-
ity, ≤ 1 µg/dL; Environmental Sciences
Associates, Inc., Chelmsford, MA).
Exploratory activity: baseline and ampheta-
mine induced. Exploratory activity was assessed
in year-old male and female mice (six to nine
per sex per group). Activity was measured in a
fully enclosed Optovarimax behavioral moni-
tor (40 × 40 × 40 cm; 16 infrared photo-
receptor beams per X–Y side; Columbus
Instruments, Columbus, OH) located in a
quiet room with dim lighting. Data were
recorded based on the number of laser-beam
breaks made each 5-min period. Novel
exploratory activity data were collected for
30 min after a 15-min acclimation period.
Two weeks later, the same animals were given
a 15-min acclimation period, weighed, and
injected (ip) with 3 mg/kg d-amphetamine sul-
fate (Sigma A-5880; Sigma-Aldrich, St. Louis,
MO), and placed in the recording chamber.
Five minutes later, a 3-hr locomotor activity
recording began. This dose of amphetamine
avoided stereotypic behavior from competing
and interfering with locomotor behavior (Zhu
et al. 2006).
Rotarod. Interlimb balance and coordina-
tion were assessed in year-old male and female
mice (six to eight per sex per group) with a
rotarod (Columbus Instruments). Mice were
trained to stay on top of a stationary rod (3-cm
diameter), then at a constant speed of 5 rpm for
90 sec. Mice were tested 3 times the day after
they mastered the task, with a 1-hr intertrial
interval. For each trial, the rod rotated at 5 rpm
for 30 sec, and the speed was increased 0.1 rpm
until the mouse fell off. The three trials were
averaged to obtain one rotarod latency score
(seconds) for each mouse.
Running wheel activity. Year-old male
mice (six per group) were given access to
Wahman-type running wheels equipped with
counters that recorded the distance (meters)
traveled. Running wheels were in a room des-
ignated solely for this purpose. For ﬁve con-
secutive dark cycles, individual mice were
placed in clean cages with an attached exercise
wheel and food and water.
High-performance liquid chromatography
(HPLC) studies. Four weeks after the last
behavioral experiment, aged male mice (four
to seven per treatment group) were sacriﬁced
by decapitation between 1000 hours and 1200
hours to avoid possible circadian effects.
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Table 1. Maternal and litter measures for control C57BL/6 mice.a
Maternal and litter measures Outcome results
Maternal
Dams’ ﬂuid consumption for 14 days prior to mating (mL/day) 4.78 ± 0.24
Dams’ ﬂuid consumption during gestation (mL/day) 5.32 ± 0.32
Dams’ ﬂuid consumption from PN1 until PN10 (mL/day) 6.81 ± 0.53
Dams’ weight 14 days prior to mating (g) 19.91 ± 0.53
Dams’ weight at mating (g) 21.12 ± 0.39
Dams’ weight gain during pregnancy (g) 6.23 ± 0.49
Mating success rate (%) 91.6 ± 1.7
Litter
Length of gestation (days) 19.5 ± 0.2 days
Mean litter size (pups) 9.8 ± 0.5 pups
Sex distribution at birth 54% males; 46% females
Litter mortality (dead pups/litter) 0.6 ± 0.2
Pup mortality during lactation (%) 9.4 ± 0.3
aMean ± SE values are from 12 to 17 control dams and litters.
Figure 1. Gestational lead exposure (GLE) paradigm. Female mice were exposed to lead for 14 days prior to
conception to establish a steady-state blood lead level before mating. After mating, dams were exposed to
lead throughout gestation, and embryonic day 0 (E0) exposure was continued from birth (PN0) until PN10. This
GLE model ensures that offspring were exposed for a period equivalent to the duration of human gestation.
Rodent model for human equivalent gestational lead exposure
Lead exposure
12 months E0 PN0 PN10 PN21
Aged
adult
Start
lead
Mating Birth Stop
lead
Weaning
Gestational development
2 weeks 3 weeksBrains were rapidly removed, and striatum
and forebrain samples were dissected and
placed in ice-cold 0.2 N perchloric acid and
frozen at –80°C. Frozen samples were homog-
enized and centrifuged at 4°C. The super-
natant was analyzed for the concentration of
dopamine ([DA])and its major metabolite 3,4-
dihydroxyphenylacetic acid ([DOPAC]) by
HPLC with electrochemical detection as
described (Petroske et al. 2001). DA and
DOPAC are expressed as nanograms per milli-
gram protein. [DOPAC]/[DA] ratios were
used as a measure of DA utilization (Boireau
et al. 1990).
Statistical analysis. Body weight, behav-
ioral, and neurochemical studies used one
animal per litter, and the group data were ana-
lyzed by a one-way analysis of variance
(ANOVA), with or without repeated measures.
Male and female [BPb] data were analyzed
using a two-way ANOVA. After ANOVA
analyses, post-hoc multiple comparisons used
the Tukey Honestly Signiﬁcant Difference test
(KaleidaGraph; Synergy Software, Reading,
PA; Minitab Inc., Prentice-Hall, Edgewood
Cliffs, NJ). Data are presented as mean ± SE,
and the difference from controls was consid-
ered signiﬁcant at p < 0.05.
Results
Animal models and blood lead levels. Fluid
consumption and body weight of GLE dams
exposed to water or lead from 14 days prior to
conception until birth were measured, and ges-
tational and litter measures were recorded. All
control values (Table 1) were similar to those
previously reported (Kelley and Middaugh
1996; Middaugh et al. 1988). There were no
statistical differences between control and GLE
groups on any measure (data not shown).
A two-way ANOVA revealed that [BPb] of
male and female littermates were not signiﬁ-
cantly different for any GLE or PLE treatment
condition. Figure 2A shows that control, and
low-, moderate-, and high-dose GLE produced
concentration-dependent increases in [BPb] at
PN0–10, with peak [BPb] of ≤ 1, ≤ 10, 27,
and 42 µg/dL, respectively. By PN30, [BPb] in
GLE mice were not signiﬁcantly different from
controls. There were no statistically signiﬁcant
differences between control and PLE groups
on any maternal or litter measure (He et al.
2003; data not shown). Figure 2B shows that
control, and low-, and moderate-dose PLE
produced signiﬁcant concentration-dependent
increases in [BPb] from PN7–21 with peak
[BPb] of ≤ 1, 10, and 26 µg/dL, respectively.
By PN60, the [BPb] in PLE mice were not
signiﬁcantly different from controls.
Body weights. Figure 3 shows that GLE had
no signiﬁcant effect on body weight at PN0,
10, and 60, although by PN60, males in all
groups weighed signiﬁcantly more than females
(Figure 3C). Similarly, there were no signiﬁcant
treatment-related differences in body weight at
6 or 10 months of age (data not shown) or at
1 year in female GLE mice (Figure 3D). In
contrast, year-old low- (+26%), moderate-
(+21%), and high-dose (+13%) male GLE
mice weighed signiﬁcantly more than controls
(Figure 3D). There were no signiﬁcant treat-
ment-related effects of PLE on body weight
during development, aging, or at 12 months of
age (Figure 3E).
Gestational lead-induced effects in aged male mice
Environmental Health Perspectives • VOLUME 116 | NUMBER 3 | March 2008 357
Figure 2. Blood lead concentration of GLE (A) and PLE (B) offspring. (A) GLE groups at PN0 and 10 but not
at PN30 were signiﬁcantly different from controls. (B) PLE groups at PN7, 14, 21, and 45 but not PN60 were
significantly different from controls. For this and all subsequent figures, lead acetate drinking solutions
contained the following: low lead = 0.005% (27 ppm), moderate lead = 0.01% (55 ppm), and high lead =
0.02% (109 ppm). Values are mean ± SE.
*p < 0.05; **p < 0.01.
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Figure 3. Body weights of GLE (A–D) and PLE (E) offspring from birth to 12 months of age. There were no
signiﬁcant treatment-related differences in body weight for GLE males (M) or females (F) at (A) birth, (B)
PN10, and (C) PN60. However, by 12 months of age (D) GLE males but not females were signiﬁcantly heav-
ier than controls. Low-dose GLE males were significantly heavier than high-dose GLE males. (E) There
were no signiﬁcant treatment-related differences in body weight for PLE mice during development, aging,
(data not shown) or at 12 months of age. Values are mean ± SE.
*p < 0.05; **p < 0.01.
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1 YearExploratory activity and running wheel
activity. When placed in an activity chamber
for 30 min for the ﬁrst time, 1-year-old control
male (Figure 4A) and female mice (Figure 4B)
exhibited similar levels of exploratory activity.
However, male mice in the low- and high-dose
GLE groups were signiﬁcantly less active than
control mice: total mean decrease was 52% and
35%, respectively (Figure 4A). Low-dose GLE
males were signiﬁcantly less active than high-
dose GLE males. In contrast, there were no
treatment-related differences for female mice
(Figure 4B). Because year-old GLE males
weighed more than age-matched control males
(Figure 3D), we addressed the possibility that
excess body weight made the GLE males lethar-
gic and less active. This hypothesis was not con-
firmed, as there were no treatment-related
differences in male running wheel activity
(Figure 4C).
Amphetamine-induced motor activity.
Amphetamine-induced motor activity was
recorded in year-old mice (Figure 5). Initial
data analysis suggested that there were no
differences between treatment groups,
although males (Figure 5A, C) were 50% less
active after amphetamine challenge than
females (Figure 5B, D). Because the baseline
exploratory activity in GLE males (Figure 4A)
but not in females (Figure 4B) was signiﬁcantly
decreased, we conducted a more detailed
analysis of the ﬁrst 30 min of amphetamine-
induced motor activity. Figure 5C and D
reveals no apparent between-group differences
in amphetamine-induced motor activity.
However, when we subtracted the baseline
activity counts from the amphetamine-induced
activity counts for the first 30 min, the net
motor activity revealed that low- and high-dose
GLE males exhibited a signiﬁcant (2-fold) over-
all heightened sensitivity to amphetamine stim-
ulation (Figure 5E). GLE females exhibited no
overall change in sensitivity to amphetamine-
stimulated motor behavior (Figure 5F).
Leasure et al.
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Figure 4. Spontaneous locomotor activity and
exercise wheel activity in year-old GLE mice.
(A) Compared with controls, both low-dose and
high-dose GLE males were signiﬁcantly less active.
Except at 5 and 10 min, the low-GLE mice were sig-
niﬁcantly slower than high-dose GLE mice. (B) There
were no signiﬁcant differences between groups in
female mice. (C) There were no significant differ-
ences between groups of male mice in their sponta-
neous wheel running activity. Values are mean ± SE. 
*p < 0.05.
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Figure 5. Amphetamine-induced motor activity in year-old GLE mice. There were no apparent differences
between treatment groups for either male (A) or female (B) mice, although males exhibited significantly
less cumulative amphetamine-induced activity (3 mg/kg, ip) than females over the 3-hr period. There were
no apparent differences in amphetamine-induced motor activity between treatment groups for male (C) or
female mice (D), although males had signiﬁcantly less cumulative activity than females during the ﬁrst 30
min. The amphetamine-minus-baseline activity score for the ﬁrst 30 min revealed that GLE males exhibited
a signiﬁcantly more rapid onset and greater response to amphetamine relative to age-matched controls
(E), whereas the females showed no overall change in the net amphetamine behavioral response (F).
Values are mean ± SE.
*p < 0.05.
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D
E FRotarod performance. The mean latency to
fall from the rotarod was not different in year-
old male and female control mice or female
GLE mice (Figure 6). In contrast, all GLE
males had signiﬁcantly shorter latencies to fall
from the rotarod compared with age-matched
controls. In addition, the mean rotarod perfor-
mance of low-dose GLE males was signiﬁcantly
poorer than that of high-dose GLE males. 
Striatal and forebrain DA metabolism.
High-dose GLE signiﬁcantly increased striatal
[DA] by 23% and [DOPAC] by 58%, whereas
low-dose GLE signiﬁcantly elevated [DOPAC]
by 17% (Figure 7A). Striatal DA utilization
was unchanged in GLE mice (Figure 7C). In
the forebrain, high-dose GLE significantly
increased [DA] by 63% and [DOPAC] by
149%, and low-GLE significantly increased
[DOPAC] by 69% (Figure 7B). However,
in the forebrain low-GLE decreased [DA]
by 30%, and both low- and high-dose
GLE increased DA utilization (Figure 7C).
Moreover, the increased forebrain DA utili-
zation was significantly greater in low-
dose (+133%) than in high-dose (+50%)
GLE mice.
Discussion
We report six novel results. First, a new and
toxicologically relevant murine model of
human equivalent low-level GLE was estab-
lished. Second, the long-term physiological,
behavioral, and neurochemical effects of low-
level GLE were examined in year-old male and
female mice. Third, sex-specific increases in
body weight were observed in year-old GLE
male mice. Fourth, male-speciﬁc alterations in
spontaneous and amphetamine-induced
motor behaviors were found in year-old GLE
mice. Fifth, alterations in striatal and forebrain
DA metabolism were present in year-old male
GLE male mice. Sixth, and most important,
GLE produced nonmonotonic dose-depen-
dent responses because the alterations were
consistently larger in the low-dose than in the
high-dose GLE group. These responses are
characteristic of inverted U-shaped dose–
response curves often observed in lead neuro-
toxicity studies (Davis and Svendsgaard 1990).
One of the most compelling ﬁndings in the
present study is that GLE acted as a delayed
obesogen. Specifically, by 1 year of age male
GLE mice were obese (Pizzi and Barnhart
1976), and the weight gain was greater in low-
and moderate-dose than in high-dose GLE
mice. This nonmonotonic characteristic is sup-
ported by reports showing that lifetime expo-
sure to 5- to 20-fold higher lead levels either did
not affect body weight of 14-month-old male
or female rats (Verlangieri 1979) or decreased it
in adult rats (Carmichael et al. 1981).
Obesity and related disorders such as dia-
betes and cardiovascular disease have increased
dramatically in children and adults during 
the past 25 years (Hedley et al. 2004).
Additionally, epidemiological studies show a
strong association between obesity and a vari-
ety of cancers (Calle and Kaaks 2004).
Although the molecular mechanism responsi-
ble for the lead-induced delayed obesity is
unknown, there are several candidates. First,
genetic polymorphisms in the vitamin D
receptor, insulin-induced gene 2 (INSIG2),
and FTO genes (fat mass and obesity associ-
ated genes) (Frayling et al. 2007; Ye et al.
2001) have been linked to obesity and meta-
bolic disorders. The possibility that GLE pro-
duced polymorphisms in the vitamin D
receptor is suggested by findings that lead
inhibits vitamin D3 receptor–regulated cal-
cium metabolism (Schanne et al. 1992), and
vitamin D receptor polymorphisms elevate
[BPb] and tibial [BPb] (Rezende et al. 2008;
Schwartz et al. 2000). Second, hypothalamic
dopaminergic receptors are associated with
genetic obesity in mice (el-Refai and Chan
1986). Developmental studies have linked lead
to hypothalamic dopaminergic dysfunction
and altered hypothalamic–pituitary–adrenal
axis (Cory-Slechta et al. 2004; Govoni et al.
1984). Third, the environmental obesogen
hypothesis states that dietary and environmen-
tal chemicals disrupt endocrine signaling path-
ways and thereby contribute to obesity
(Baillie-Hamilton 2002; Heindel 2003).
Recent studies suggest that fetal exposure to
organotins produce obesity in male rats by
activating certain nuclear receptors (Grun
et al. 2006). Thus, lead-induced delayed obe-
sity could occur via a variety of endocrine/
metabolic mechanisms.
The spontaneous locomotor activity and
rotarod performance were decreased in GLE
male mice, with greater effects seen in the low-
dose than in the high-dose GLE group. These
curvilinear results are consistent with “negative”
dose–response curves, as high-dose GLE pro-
duced less deviation from control than did low-
dose GLE (Davis and Svendsgaard 1990).
Because year-old GLE males were signiﬁcantly
heavier than controls, we tested whether these
mice were lethargic and less active on a running
wheel. Because all three groups ran comparable
distances, the results indicate that the GLE-
induced motor alterations were not caused by a
lack of motivation or inefﬁcient locomotion.
We hypothesized that the novel environ-
ment differentially increased the stress level of
aged GLE male mice, which subsequently
altered dopaminergic signaling and decreased
locomotor activity. Consistent with this pro-
posal are recent data showing that moderate-
to-high-level lead exposure during gestation
Gestational lead-induced effects in aged male mice
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Figure 6. Rotarod performance in year-old GLE mice.
Control male and female mice performed similarly
on the rotarod task. Compared with age-matched
controls, GLE males had signiﬁcantly shorter laten-
cies to fall from the rotarod. Low-dose GLE males
fell off the rotarod signiﬁcantly faster than high-dose
GLE males. In contrast, there were no treatment-
related differences between female mice. Values
are mean ± SE.
*p < 0.05; **p < 0.01. 
100
80
60
40
20
0
L
a
t
e
n
c
y
 
t
o
 
f
a
l
l
 
f
r
o
m
 
r
o
t
a
r
o
d
 
(
s
e
c
)
Male
Control
Low lead
High lead
Female
*
**
Figure 7. Striatal and forebrain content of DA and DOPAC and DA utilization in year-old GLE male mice. (A) High-dose GLE increased striatal [DA] and both GLE
doses elevated striatal [DOPAC]. (B) Low-GLE decreased forebrain [DA], whereas high-dose GLE increased forebrain [DA]. Both low and high-dose GLE
increased forebrain [DOPAC]. (C) Dopamine utilization ([DOPAC]/[DA]) ratio was unchanged in the striatum of GLE mice, whereas the ratio increased in the fore-
brain of both low- and high-dose GLE mice. Values are mean ± SE.
*p < 0.05; **p < 0.01.
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A B Cand throughout lactation produced a) elevated
basal corticosterone concentrations in male off-
spring, b) a decrease in novel exploratory
behavior of males, and c) decreased ﬁxed-inter-
val response rates in males (Cory-Slechta et al.
2004; Moreira et al. 2001; Virgolini et al.
2004). However, the role of DA is still
unknown, as both adult male and female rats
exhibited dopaminergic dysfunction in several
brain regions (Cory-Slechta et al. 2004). In
summary, our findings reveal that low-level
GLE produced the most profound and endur-
ing alterations in locomotor activity, another
example of nonmonotonic responses. Further-
more, the results suggest that a coordinated
dysregulation of the hypothalamic–pituitary–
adrenal axis and dopaminergic systems might
underlie these changes.
Amphetamine enhances low rates of
responding and depresses high rates of respond-
ing, which produces the classic inverted
U-shaped dose–response effect (Glick and
Milloy 1973). Because year-old GLE male but
not female mice had decreased locomotor activ-
ity compared with age- and sex-matched con-
trols, we reasoned that amphetamine would
differentially increase locomotor behavior in
GLE males and produce no differential loco-
motor effect in year-old female mice. Indeed,
amphetamine increased the locomotor activity
of both low- and high-dose GLE mice com-
pared with controls; larger effects occurred in
low-dose GLE mice. Although the DA trans-
porter is a major target site of amphetamine
(Madras et al. 2005), dopamine D3 receptors in
the ventral striatum also regulate the sensitivity
to the locomotor-stimulating effects of amphet-
amine (McNamara et al. 2006). Although
alterations in striatal DA metabolism as well as
D1 and D2 dopamine receptors occur in devel-
opmentally lead-exposed rats (Cory-Slechta
1997; Ma et al. 1999), there are at present no
studies on the dopamine D3 receptors.
Developmental lead exposure is associated
with attention-deficit/hyperactivity disorder
(ADHD) in children (Bellinger et al. 1994;
Braun et al. 2006), which is among the most
common childhood and adult neurological dis-
orders (Kessler et al. 2006). Neuroanatomical
and functional abnormalities in the prefrontal
cortex are reported to underlie this deficit
(Barkley et al. 1992). Moreover, recent func-
tional magnetic resonance imaging studies
revealed a diminished activation in the frontal
cortex of young adults after developmental lead
exposure (Yuan et al. 2006). It is unknown
whether GLE and/or early PLE produce the
greatest risk for childhood ADHD. The contri-
bution of GLE to adult-onset ADHD, which
also has a 1.6 male–female odds ratio as
childhood ADHD (Kessler et al. 2006), is
unknown. Our amphetamine-stimulated loco-
motor results in year-old male GLE mice are
consistent with the U-shaped therapeutic
outcome for ADHD and suggest that low-level
GLE merits consideration as a causative factor
to lead-induced ADHD in children and adults.
Both groups of aged GLE male mice were
impaired on the rotarod, which is a test of
interlimb balance and coordination. Low-
dose GLE males were significantly more
impaired than high-dose GLE males.
Consistent with the negative dose–response
curve, rotarod activity was unchanged in
adult male rats exposed to 5- to 40-fold
higher lead levels during gestation and lacta-
tion or lifetime (Ma et al. 1999; Moreira et al.
2001). These rotarod results are reminiscent
of the poorer ﬁne motor control, visual motor
function, and postural balance found in chil-
dren, adolescents, and young adults with low-
to-moderate developmental lead exposure
(Baghurst et al. 1995; Bhattacharya et al.
1990, 2006; Ris et al. 2004; Wasserman et al.
2000; Winneke et al. 1990). Interestingly,
there is an increased risk of neuromotor
deﬁcits in males (Ris et al. 2004). Our results
suggest that low-level GLE contributes to per-
sistent neuromotor and balance deﬁcits and is
a risk factor for injuries in older males.
Because body weight and behavioral dif-
ferences were found only in year-old GLE
male mice, neurochemical analyses were con-
ducted in these mice. GLE female mice are
being aged for future studies. Numerous stud-
ies have reported changes in adult rat brain
DA metabolism after moderate-to-high post-
natal or lifetime lead exposure (Cory-Slechta
1997; Ma et al. 1999). However, the present
report is the first study to use a GLE model
and examine neurochemical changes in aged
mice. We found that low-dose GLE decreased
forebrain [DA] and increased striatal and
forebrain [DOPAC], whereas high-dose GLE
increased both striatal and forebrain [DA]
and [DOPAC]. These GLE-induced changes
resulted in nonmonotonic increases in fore-
brain DA utilization but no change in striatal
DA utilization. The inverted U-shaped dose-
response function for forebrain DA utilization
correlates with the GLE-induced alterations
in weight gain and neuromotor functions. For
two reasons it is unlikely that these dopamin-
ergic changes resulted from a direct effect of
lead in year-old mice. The peak brain [Pb] in
the low- and high-dose GLE mice on PN10
were equivalent to 0.44 and 1.2 µM, respec-
tively, and the brain [Pb] is not different from
controls after PN30 (data not shown). In
addition, 3–250 µM Pb2+ is required to
inhibit rat brain tyrosine hydroxylase activity,
depolarization-evoked and spontaneous DA
release, and DA uptake (Jadhav and Ramesh
1997; Minnema et al. 1986; Ramsay et al.
1980). Thus, further multidisciplinary molec-
ular, biochemical, bioinformatic, and imaging
studies are needed to support our findings
and provide mechanistic insight.
In summary, our results show that GLE
mice with peak [BPb] ≤ 10 µg/dL, the current
low level of concern (CDC 1991), have per-
manent sex-speciﬁc motor abnormalities and
late-onset obesity. The nonmonotonic dose-
dependent responses reveal that low-level GLE
produces the most adverse effects. These data
raise complex issues for risk assessment and
indicate that lifetime measures of dose–
response toxicant exposure should be a compo-
nent of the neurotoxic risk assessment process.
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